Roche Taps Atavistik Allosteric Platform

Company Atavistik Bio / Roche Event Type Research Collaboration and License Agreement Modality Allosteric Small Molecule Asset AMPS Platform Discovery Programs Target Undisclosed (Multiple Cardiometabolic Targets) Disease Area Cardiovascular, Renal and Metabolic Disease Summary Roche agreed to pay Atavistik Bio $70 million upfront for a…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

GSK Acquires Nuvalent for $10.6B
Curium Agrees to Acquire Lantheus for Up to $8 Billion
Typewriter Launches with $56 Million for All-RNA Gene Insertion
Ligand Funds AvenCell CAR T Pipeline